Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes
- 31 January 2013
- journal article
- review article
- Published by Elsevier BV in Contemporary Clinical Trials
- Vol. 34 (1), 1-9
- https://doi.org/10.1016/j.cct.2012.09.003
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Stakeholder participation in comparative effectiveness research: defining a framework for effective engagementJournal of Comparative Effectiveness Research, 2012
- Economic Evaluation of Genomic Test–Directed Chemotherapy for Early-Stage Lymph Node–Positive Breast CancerJNCI Journal of the National Cancer Institute, 2011
- Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor–Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical FactorsJournal of Clinical Oncology, 2011
- How Best To Engage Patients, Doctors, And Other Stakeholders In Designing Comparative Effectiveness StudiesHealth Affairs, 2010
- The Value of Value of InformationPharmacoEconomics, 2010
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialThe Lancet Oncology, 2010
- Optimal clinical trial design using value of information methods with imperfect implementationHealth Economics, 2009
- Randomized Phase III Clinical Trial Designs for Targeted AgentsClinical Cancer Research, 2008
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- An economic approach to clinical trial design and research priority-settingHealth Economics, 1996